Navigation Links
Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
Date:3/4/2008

Phase 2b Trial Expected to Begin in the Second Quarter of 2008

SAN DIEGO, March 4 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Mpex orphan drug designation for levofloxacin solution for inhalation for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis. Levofloxacin is the active pharmaceutical ingredient in MP-376, the company's proprietary levofloxacin solution for inhalation.

Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa. Chronic pulmonary infections are difficult to eradicate and are implicated as the major cause of deterioration of pulmonary function and associated morbidity and mortality in CF patients. Chronic infection is associated with pulmonary exacerbations due to bacterial overgrowth, and a decrease in lung function over time from inflammation triggered by bacteria and their toxins.

"Obtaining orphan drug designation for MP-376 in cystic fibrosis is an important milestone for the program," stated Daniel Burgess, President and Chief Executive Officer of Mpex Pharmaceuticals, Inc. "This helps reinforce our belief that MP-376 has the potential to provide a valuable new treatment option in the management of cystic fibrosis. We look forward to working with CF patients, treatment providers and the FDA to rapidly advance this product candidate through to commercialization."

Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 Americans annually. Orphan drug designation will entitle Mpex to a seven-year period of exclusive marketing rights for MP-376 for the orphan indication following the date of the drug's marketing approval by the FDA. Orphan status also enables Mpex to apply for research funding, tax credits for certain research expenses, and a waiver from FDA user fees.

About MP-376

MP-376 is a proprietary formulation of levofloxacin that has been designed by Mpex scientists to enable aerosol administration. Levofloxacin is a powerful antibiotic that has been widely used in a variety of indications for over a decade and has established safety and efficacy when administered orally or intravenously against many bacterial pathogens including Pseudomonas aeruginosa. Administration of MP-376 with a high efficiency nebulizer to the lungs allows for the delivery of high concentrations of active drug directly to the site of infection, while minimizing systemic exposure. Mpex believes this approach has the potential to improve bacterial killing and reduce resistance development versus traditional oral or IV routes of administration.

Mpex recently completed a multi-center, 14-day placebo controlled clinical trial with MP-376 in 40 CF patients. Based on these results and consultations with the FDA and the Therapeutics Development Network (TDN) of the Cystic Fibrosis Foundation, the company expects to initiate a Phase 2b clinical trial in approximately 140 CF patients in the second quarter of 2008. Several dosing regimens of MP-376 will be compared, including once daily administration schedules. Results from this trial, if successful, are expected to enable the company to select dosing regimens for the pivotal Phase 3 clinical program in this indication.

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's lead product candidate, MP-376, is being developed clinically for the aerosol treatment of chronic respiratory tract infections such as those found in cystic fibrosis patients. The company has also built a discovery and development platform and intellectual property estate around inhibitors of bacterial multi-drug resistant (MDR) efflux pumps (EPIs). Bacterial efflux of antibiotics is a leading source of multi-drug resistance, particularly in gram-negative organisms. Mpex compounds have been shown preclinically to overcome efflux-based resistance to multiple classes of antibiotics in both in vitro and in vivo studies.


'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Animal Imaging
2. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
3. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
5. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Raptor Pharmaceuticals Acquires Orphan Clinical Program
8. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
9. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
10. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
11. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... NE (PRWEB) , ... January 12, 2017 , ... ... hiring of Stephen Beck, who will work in the company’s Lincoln office as a ... chemical processes to design control systems for customers in the life science manufacturing and ...
(Date:1/12/2017)...   Protein Sciences Corporation , a leading ... Influenza Vaccine ®, announced today that its lead ... results and induced strong neutralizing antibodies against the ... expected to advance into human clinical trials in ... of Technology in Immunobiologicals of the Oswaldo Cruz ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... Limfinity® Cloud, RURO has enhanced the platform to accommodate increasingly complex and ... rapid data searching, and more. In addition to these improvements, the latest ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a graduate student, ... the pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages those diseases ... Now, as an assistant professor of biology and biotechnology at Worcester Polytechnic Institute ...
Breaking Biology Technology:
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms of ... 2016 to 2021. The market is estimated to be USD 442.7 ... 2021. The growth of the biometric vehicle access system market is ...
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... ... Research and Markets has announced the addition of the "Global ... The report forecasts the global military biometrics market to grow at a ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):